Carlos Omphroy, MD
Ophthalmology · Mililani, HINPI 1437165396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,932 and has fallen 56.3% since, to $843 in 2025.
Across 212 payments — averaging $44.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Alcon$1K
- Bausch & Lomb Americas Inc.$978
- Amgen$778
- AbbVie$727
- Bausch & Lomb, A Division Of Bausch Health US, LLC$705
- plus $3K from 16 others
What the payments were for
- Travel & lodging$50%
- Food & beverage$9,306100%
- Other$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 20 | $1,940 |
| Alcon | 31 | $1,258 |
| Bausch & Lomb Americas Inc. | 17 | $978 |
| Amgen(2 entities) | 25 | $778 |
| AbbVie(2 entities) | 28 | $727 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $705 |
| Aerie Pharmaceuticals, Inc. | 19 | $652 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $479 |
| Sight Sciences, Inc. | 5 | $464 |
| Quidel Corporation | 7 | $364 |
| Tarsus Pharmaceuticals, Inc. | 11 | $345 |
| Novartis | 8 | $178 |
| Oyster Point Pharma, Inc. | 6 | $164 |
| Sun Pharmaceutical Industries Inc. | 4 | $82 |
| Kala Pharmaceuticals, Inc. | 3 | $55 |
| Boehringer Ingelheim | 2 | $43 |
| Genentech USA, Inc. | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Welch Allyn | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$592
- Rocklatan$592
- OMNI(R) SURGICAL SYSTEM (US)$422
- enVista MX60 IOL$400
- VYZULTA$392
- TEPEZZA$391
- iStent inject Trabecular Micro-Bypass Stent System$296
- iStent inject W$252
- LOTEMAX SM$250
- Tecnis Multifocal Family of 1-piece IOLS$179
- iDoseTR$172
- iStent Trabecular Micro-Bypass System Model iS3$153
- TORIC$151
- iDose$146
- ARGOS$140
- XDEMVY$134
- Tecnis Simplicity$133
- KXL System$133
- Photrexa$133
- LenSx$130
How this compares
$9,331 in reported general payments places this provider in the 75th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 113 | $88,073 |
| XdemvyLotilaner | 30 | $54,743 |
| XiidraLifitegrast | 41 | $50,672 |
| VyzultaLatanoprostene Bunod | 72 | $44,809 |
| RocklatanNetarsudil Mesylat/Latanoprost | 47 | $34,868 |
| MieboPerfluorohexyloctane/Pf | 16 | $20,319 |
| RhopressaNetarsudil Mesylate | 21 | $19,751 |
| Brimonidine Tartrate | 78 | $16,742 |
| TyrvayaVarenicline Tartrate | 11 | $11,800 |
| Bimatoprost | 44 | $9,942 |
| Prednisolone Acetate | 178 | $7,303 |
| Latanoprost | 226 | $4,987 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 57 | $4,225 |
| Bromfenac Sodium | 33 | $3,798 |
| Bepotastine Besilate | 16 | $2,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $978 | $115,799129 claims |
| AbbVieLumigan | $727 | $88,073113 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $345 | $54,74330 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $652 | $54,61968 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $164 | $11,80011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Mililani
- Jeffrey RutgardMililani$10K
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Gregg KokameAiea$73K
- Rupa WongHonolulu$72K
- William WongAiea$40K
- Luis OmphroyAiea$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.